Enumera Molecular Acquires Progenity Liquid Biopsy Tech, Raises $12.5M in Series A Round

Progenity said on Thursday that it has divested its collection of discovery-stage biochemical and bioinformatics technologies for rapid, low-cost liquid biopsy testing to newly formed Enumera Molecular.